Oncogenic-RAS-signal dependent lethal compounds
Compounds with cancer cell specific lethality are provided. In particular, RAS-selective lethal compounds and compositions are provided. Also provided are methods of screening for such compounds and methods of treating a condition in a mammal, by administering to the mammal a therapeutically effective amount of such compounds or compositions.
1. A compound selected from the group consisting of:
and mixtures thereof, or a N-oxide, crystalline form, or pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , which is:
or a N-oxide, crystalline form, or pharmaceutically acceptable salt thereof.
3. The compound according to claim 2 , which is enantiomerically pure.
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an enantiomerically pure RAS-selective lethal compound having the structure:
or a N-oxide, crystalline form, or pharmaceutically acceptable salt thereof.